{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:49:44Z","timestamp":1740134984176,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal cancer in the UK has remained relatively stable over the past 25\u2009years, vulval cancer rates are increasing. A body of literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the economic burden. The objective of this study was to quantify the costs of treating these cancers on the National Health Service (NHS) in England.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and invasive vaginal and vulval lesions in England.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The study showed that for the 5\u2009years from 2009\/2010 to 2014\/2015 the total cost associated with pre-cancerous and invasive vaginal and vulval lesions was over \u00a314 million per year on average (95% of which was attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost (\u00a38.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended outpatient settings for pre-cancerous and invasive disease of the vagina and vulva.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The results indicate that vaginal and vulval cancer cost the English health care system over \u00a314 million per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS resources, it is important that future economic evaluations of such preventative measures consider the full burden of HPV related disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-08545-4","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T13:03:32Z","timestamp":1586178212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The costs of treating vaginal and vulval cancer in England (2009\u20132015)"],"prefix":"10.1186","volume":"20","author":[{"given":"Stephanie","family":"Stephens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Coles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"8545_CR1","unstructured":"World Health Organisation Human papillomavirus (HPV) and cervical cancer. 2018. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed 21 Nov 2018."},{"issue":"Suppl 3","key":"8545_CR2","first-page":"S3\/52","volume":"24","author":"AN Burchell","year":"2006","unstructured":"Burchell AN, Winer RL, de Sanjos\u00e9 S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(Suppl 3):S3\/52\u201361.","journal-title":"Vaccine"},{"key":"8545_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ygyno.2009.09.021","volume":"115","author":"X Castellsagu\u00e9","year":"2009","unstructured":"Castellsagu\u00e9 X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115:S15\u201323.","journal-title":"Gynecol Oncol"},{"key":"8545_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664\u201370.","journal-title":"Int J Cancer"},{"key":"8545_CR5","unstructured":"Cancer research UK Cancer research UK. Vaginal Cancer Statistics. http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/vaginal-cancer. Accessed 20 Nov 2018."},{"key":"8545_CR6","unstructured":"Cancer research UK Cancer research UK. Vulval cancer statistics. http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/vulval-cancer. Accessed 20 Nov 2018."},{"key":"8545_CR7","unstructured":"Royal College of Obstetricians and Gynaecologists (2006) Management of vulval cancer."},{"key":"8545_CR8","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1016\/j.vaccine.2013.06.060","volume":"31","author":"M Fesenfeld","year":"2013","unstructured":"Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786\u2013804.","journal-title":"Vaccine"},{"key":"8545_CR9","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","volume":"2","author":"M Jit","year":"2014","unstructured":"Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2:e406\u201314.","journal-title":"Lancet Glob Health"},{"key":"8545_CR10","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1016\/j.vaccine.2014.07.099","volume":"32","author":"J-F Laprise","year":"2014","unstructured":"Laprise J-F, Drolet M, Boily M-C, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malag\u00f3n T, Brisson M. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 2014;32:5845\u201353.","journal-title":"Vaccine"},{"key":"8545_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12913-017-2297-x","volume":"17","author":"H Van Minh","year":"2017","unstructured":"Van Minh H, My NTT, Jit M. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC Health Serv Res. 2017;17:353.","journal-title":"BMC Health Serv Res"},{"key":"8545_CR12","unstructured":"NHS Digital Hospital Episode Statistics (HES) database. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics. Accessed 13 Aug 2019."},{"key":"8545_CR13","unstructured":"SUS+ PbR Reference Manual Implementation of National Tariff\/Payment by Results (PbR) in the Secondary Uses Service (SUS) v4.64. London: NHS Digital; 2019. Available: https:\/\/digital.nhs.uk\/services\/secondary-uses-service-sus\/payment-by-results-guidance. Accessed 23 Mar 2020."},{"key":"8545_CR14","unstructured":"A simple guide to Payment by Results. Department of Health Payment by Results Team. Leeds; 2013. Available: https:\/\/www.gov.uk\/government\/publications\/simple-guide-to-payment-by-results. Accessed 11 Mar 2019."},{"key":"8545_CR15","unstructured":"NHS Digital HRG4 2016\/17 Local Payment Grouper. https:\/\/webarchive.nationalarchives.gov.uk\/20171011051311\/http:\/\/content.digital.nhs.uk\/article\/7052\/HRG4-201617-Local-Payment-Grouper. Accessed 13 Aug 2019."},{"key":"8545_CR16","unstructured":"Department of Health and Social Care National Reference Costs 2015\u20132016."},{"key":"8545_CR17","unstructured":"NHS Digital The processing cycle and HES data quality. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics\/the-processing-cycle-and-hes-data-quality. Accessed 13 Aug 2019."},{"key":"8545_CR18","volume-title":"NHS cervical screening Programme","author":"Public Health England","year":"2016","unstructured":"Public Health England (2016) NHS cervical screening Programme. Colposcopy and Programme Management."},{"key":"8545_CR19","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626\u201336.","journal-title":"Int J Cancer"},{"key":"8545_CR20","unstructured":"Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61:192\u20136."},{"key":"8545_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/1471-0528.12459","volume":"121","author":"J Lai","year":"2014","unstructured":"Lai J, Elleray R, Nordin A, Hirschowitz L, Rous B, Gildea C, Poole J. Vulval cancer incidence, mortality and survival in England: age-related trends. BJOG Int J Obstet Gynaecol. 2014;121:728\u201338.","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"8545_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11912-014-0402-4","volume":"16","author":"K Wakeham","year":"2014","unstructured":"Wakeham K, Kavanagh K. The burden of HPV-associated anogenital cancers. Curr Oncol Rep. 2014;16:402.","journal-title":"Curr Oncol Rep"},{"key":"8545_CR23","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1016\/j.vaccine.2011.05.018","volume":"29","author":"I Borget","year":"2011","unstructured":"Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine. 2011;29:5245\u20139.","journal-title":"Vaccine"},{"key":"8545_CR24","doi-asserted-by":"crossref","unstructured":"Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198:500.e1\u2013500.e7.","DOI":"10.1016\/j.ajog.2008.03.064"},{"key":"8545_CR25","doi-asserted-by":"crossref","unstructured":"Abramowitz L, Lacau Saint Guily J, Moyal-Barracco M, Bergeron C, Borne H, Dahlab A, Bresse X, Uhart M, Cancalon C, Catella L, B\u00e9nard S. Epidemiological and economic burden of potentially HPV-related cancers in France. PLOS ONE. 2018;13(9):e0202564.","DOI":"10.1371\/journal.pone.0202564"},{"key":"8545_CR26","doi-asserted-by":"crossref","unstructured":"Olsen J, J\u00f8rgensen TR, Kofoed K, Larsen HK. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health. 2012;12:1082.","DOI":"10.1186\/1471-2458-12-1082"},{"key":"8545_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3111\/13696998.2013.793691","volume":"16","author":"E Pr\u00e9aud","year":"2013","unstructured":"Pr\u00e9aud E, Largeron N. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. J Med Econ. 2013;16:763\u201376.","journal-title":"J Med Econ"},{"key":"8545_CR28","doi-asserted-by":"publisher","first-page":"d5775","DOI":"10.1136\/bmj.d5775","volume":"343","author":"M Jit","year":"2011","unstructured":"Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011;343:d5775.","journal-title":"BMJ"},{"key":"8545_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ijc.31139","volume":"142","author":"CL Rasmussen","year":"2018","unstructured":"Rasmussen CL, Sand FL, Hoffmann Frederiksen M, Kaae Andersen K, Kjaer SK. Does HPV status influence survival after vulvar cancer?: influence of HPV status on survival after vulvar cancer. Int J Cancer. 2018;142:1158\u201365.","journal-title":"Int J Cancer"},{"key":"8545_CR30","unstructured":"Jo\u2019s Cervical Cancer Trust Long term consequences of cervical cancer and its treatment 2017."},{"key":"8545_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ygyno.2018.10.045","volume":"152","author":"MT Hall","year":"2019","unstructured":"Hall MT, Smith MA, Lew J-B, O\u2019Hallahan J, Fentiman G, Neal H, Sage M, Canfell K. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: transitional and long-term benefits, costs and resource utilisation implications. Gynecol Oncol. 2019;152:472\u20139.","journal-title":"Gynecol Oncol"},{"key":"8545_CR32","unstructured":"Medical Research Council NHS Health Research Authority. http:\/\/www.hra-decisiontools.org.uk\/research\/. Accessed 21 Nov 2018."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08545-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-020-08545-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08545-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T23:09:59Z","timestamp":1617664199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-08545-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8545"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-08545-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"type":"electronic","value":"1471-2458"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required as secondary analysis of HES data can be used to identify public health issues and for general medical research under existing protocol; the Health Research Authority decision tool corroborated this fact stating no ethical approval was required for this research []<b>.<\/b>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VC is an employee of MSD UK (previously known as Sanofi Pasteur MSD). AC and SS are employees of Pharmerit Ltd., which has received funding from MSD UK. RC has received expenses for attending international conferences from Sanofi Pasteur MSD and GSK, and has participated in an advisory board for Sanofi Pasteur MSD (all >\u20095\u2009years ago).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}